- Home
- RBRK vs RPRX Comparison
RBRK vs RPRX Comparison
Compare RBRK & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBRK
- RPRX
- Stock Information
- Founded
- RBRK 2013
- RPRX 1996
- Country
- RBRK United States
- RPRX United States
- Employees
- RBRK N/A
- RPRX N/A
- Industry
- RBRK
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- RBRK
- RPRX Health Care
- Exchange
- RBRK NYSE
- RPRX Nasdaq
- Market Cap
- RBRK 11.9B
- RPRX 14.2B
- IPO Year
- RBRK 2024
- RPRX 2020
- Fundamental
- Price
- RBRK $60.39
- RPRX $31.13
- Analyst Decision
- RBRK Strong Buy
- RPRX Strong Buy
- Analyst Count
- RBRK 20
- RPRX 5
- Target Price
- RBRK $71.72
- RPRX $41.60
- AVG Volume (30 Days)
- RBRK 2.8M
- RPRX 4.3M
- Earning Date
- RBRK 03-13-2025
- RPRX 05-08-2025
- Dividend Yield
- RBRK N/A
- RPRX 2.83%
- EPS Growth
- RBRK N/A
- RPRX N/A
- EPS
- RBRK N/A
- RPRX 1.91
- Revenue
- RBRK $886,544,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- RBRK $27.12
- RPRX $33.46
- Revenue Next Year
- RBRK $26.18
- RPRX $4.44
- P/E Ratio
- RBRK N/A
- RPRX $16.28
- Revenue Growth
- RBRK 41.19
- RPRX N/A
- 52 Week Low
- RBRK $28.34
- RPRX $24.05
- 52 Week High
- RBRK $80.00
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- RBRK N/A
- RPRX 33.61
- Support Level
- RBRK N/A
- RPRX $32.26
- Resistance Level
- RBRK N/A
- RPRX $34.14
- Average True Range (ATR)
- RBRK 0.00
- RPRX 0.76
- MACD
- RBRK 0.00
- RPRX -0.33
- Stochastic Oscillator
- RBRK 0.00
- RPRX 14.00
About RBRK RUBRIK INC
Rubrik Inc is a company that offers data security solutions to organizations ranging from the largest companies worldwide to mid-sized smaller customers. Its platform is architected to help organizations achieve cyber resilience, which encompasses cyber posture and cyber recovery. They enable organizations to confidently accelerate digital transformation and leverage the cloud to realize business agility.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.